Analysis of nearly 8,000 adults found 45% keep the weight off after one year As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop…


Cedars-Sinai study has important implications for understanding how a wide variety of intestinal disorders may develop The gut microbiome—the trillions of bacteria and other microbes that inhabit the gastrointestinal tract—drives a process…


A large community-based participatory research study of women of color highlights perinatal experiences and opportunities to further strengthen policies A study from community researchers partnering with Rutgers Health faculty and staff offers…


New research shows how a natural plant compound flips a built-in “avoid” switch in the mosquito brain and why that could lead to better repellents For centuries, plant-derived repellents have been used…


Professor Omar F. Khan and his team synthesized molecules with anti-inflammatory properties from long noncoding RNA, demonstrating a new paradigm in drug development A team from University of Toronto Engineering is the first to…


First-of-its-kind study may lead to precision obesity prevention, treatment strategies Higher levels of the hormone asprosin were linked to reduced weight gain in metabolically healthy postmenopausal women. Researchers analyzed data from more…


Study found men with low testosterone levels were associated with a 60% higher likelihood that prostate cancer managed on active surveillance would progress to a more aggressive state over time Research challenges the long-held belief that high testosterone fuels early-stage prostate cancer growth, suggesting instead…


Patients who are prescribed higher daily doses of the medication buprenorphine for opioid use disorder are significantly more likely to stay in treatment. Those on 17 to 24 milligrams averaged 190 days…


GLP‑1 Drugs May Fight Addiction Across Every Major Substance, According to a Study of 600,000 People
A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in…

